Testing the clinical effectiveness of Social Recovery Therapy for people with psychosis and social disability

Improving Social Recovery in Psychosis (ISRIP): a definitive randomised controlled trial and process evaluation of Social Recovery Therapy compared to treatment as usual for people with psychosis and severe social disability

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN11089633

Enrollment

410

Registered

2026-04-08

Start date

2026-07-01

Completion date

Unknown

Last updated

2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psychosis Mental and Behavioural Disorders

Interventions

This study will use an assessor-blind randomised controlled trial design to compare Social Recovery Therapy plus treatment as usual (SRT + TAU) to TAU alone, with a 9-month intervention period and a 2

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosis of non-affective psychosis 2. Working-age adult (18-65 years) 3. Social disability indicated by structured activity of 6 months 5. Under the care of secondary mental health services 6. Capacity and ability to provide informed consent

Exclusion criteria

Exclusion criteria: 1. Organic aetiology indicated for psychosis (e.g., brain injury) 2. Severe learning disability that would prevent engagement with intervention or assessments 3. Current involvement in any other interventional research study 4. Immediate serious risk to self or other

Design outcomes

Primary

Measure	Time frame
Hours per week in structured activity, assessed through the Time Use Survey at 15 months post-randomisation	—

Secondary

Measure	Time frame
1. Hours per week in structured activity assessed using the Time Use Survey at 9 months 2. Functioning assessed using Recovering Quality of Life (ReQoL), Goal-Based Outcomes, and the WHO Disability Assessment Schedule (WHO-DAS) at baseline, 9 and 15 months post-randomisation 3. Quality of life assessed using EQ-5D-5L at baseline, 9 and 15 months post-randomisation 4. Psychotic symptoms assessed using Clinical Global Impression-Schizophrenia (CGI-SCH) and Scale for the Assessment of Negative Symptoms (SANS) at baseline, 9 and 15 months post-randomisation 5. Mood assessed using Patient Health Questionnaire-9 (PHQ-9) and Generalised Anxiety Disorder-7 (GAD-7) at baseline, 9 and 15 months post-randomisation 6. Hopelessness and suicidal ideation assessed using the Beck Hopelessness Scale (BHS) at baseline, 9 and 15 months post-randomisation 7. Service engagement (contact with mental health teams) and relapse rate (number of hospitalisations) recorded at 24 months 8. Education and employment status recorded at 24 months	—

Measure

Time frame

1. Hours per week in structured activity assessed using the Time Use Survey at 9 months 2. Functioning assessed using Recovering Quality of Life (ReQoL), Goal-Based Outcomes, and the WHO Disability Assessment Schedule (WHO-DAS) at baseline, 9 and 15 months post-randomisation 3. Quality of life assessed using EQ-5D-5L at baseline, 9 and 15 months post-randomisation 4. Psychotic symptoms assessed using Clinical Global Impression-Schizophrenia (CGI-SCH) and Scale for the Assessment of Negative Symptoms (SANS) at baseline, 9 and 15 months post-randomisation 5. Mood assessed using Patient Health Questionnaire-9 (PHQ-9) and Generalised Anxiety Disorder-7 (GAD-7) at baseline, 9 and 15 months post-randomisation 6. Hopelessness and suicidal ideation assessed using the Beck Hopelessness Scale (BHS) at baseline, 9 and 15 months post-randomisation 7. Service engagement (contact with mental health teams) and relapse rate (number of hospitalisations) recorded at 24 months 8. Education and employment status recorded at 24 months

—

Countries

England, United Kingdom

Contacts

Public ContactLauren Ooi

isrip.study@uea.ac.uk-

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: May 7, 2026